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Skeletal muscle mass reflects a dynamic turnover between net protein synthesis and
degradation. In addition, satellite cell inclusion may contribute to increase muscle mass
while fiber loss results in a reduction of muscle mass. Since 2010, a few studies looked at
the involvement of the newly discovered Hippo pathway in the regulation of muscle mass.
In line with its roles in other organs, it has been hypothesized that the Hippo pathway
could play a role in different regulatory mechanisms in skeletal muscle as well, namely
proliferation and renewal of satellite cells, differentiation, death, and growth of myogenic
cells. While the Hippo components have been identified in skeletal muscle, their role in
muscle mass regulation has been less investigated and conflicting results have been
reported. Indeed, the first studies described both atrophic and hypertrophic roles of
the Hippo pathway and its effectors Yap/Taz using different biochemical approaches.
Further, investigation is therefore warranted to determine the role of the Hippo pathway
in the regulation of skeletal muscle mass. New components of the pathway will probably
emerge and unsuspected roles will likely be discovered due to its numerous interactions
with different cellular processes. This mini-review aims to summarize the current literature
concerning the roles of the Hippo pathway in the regulation of muscle mass and to
develop the hypothesis that this pathway could contribute to muscle mass adaptation
after exercise.
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INTRODUCTION
Skeletal muscle mass reflects a dynamic turnover between net protein synthesis and degradation.
In addition, satellite cell inclusion may contribute to increase muscle mass while fiber loss results
in a reduction of muscle mass. At the molecular level, skeletal muscle mass regulation is the
result of coordinated activation/inhibition of numerous signaling pathways. The first identified
signaling pathways involved in organ genesis and development were, non-exhaustively, Notch,
Wnt, transforming growth factor-beta (TGF-β), and Hedgehog (Pan, 2010). The last decades,
the mammalian target of rapamycin (mTOR) and Hippo pathways were found to be additional
regulators of organs size (Csibi and Blenis, 2012). Contrary to the mTOR pathway, which is
relatively well-described, numerous mechanisms of regulation of the Hippo pathway remain
unclear. Indeed, in Drosophila, after identification of Warts (Wts) in the 1990s, Salvador (Sav) and
Hippo in the 2000s, a first description of the Hippo scaffolded pathway was made (Pan, 2010).
First identified in mouse, and then in human, some mammalian homologs of the components of
the Hippo pathway in Drosophila are thought to be involved in organ size regulation, and many
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studies began to focus on the Hippo pathway in mammals. The
canonical Hippo pathway is now described in mammals but
crosstalks and interplays with other signaling pathways as well as
its role in organ size regulation are still unclear (Yu et al., 2015).
Recently, the Hippo pathway has been of great interest for
deep comprehension of molecular mechanisms underlying
etiology, physiopathology and treatment of pathologic
features in chronic diseases like cancers, diabetes, chronic
obstructive pulmonary disease, or renal failure. Unfortunately, its
involvement in exercise physiology and muscle mass regulation
in non-pathological states has been under-investigated up to
now (Watt et al., 2015). Therefore, this mini-review aims to
provide a focused highlight on the Hippo pathway organization,
regulation, and involvement in skeletal muscle mass regulation
in mammals and to develop the hypothesis that this pathway
could contribute to muscle mass adaptation after exercise.
ORGANIZATION OF THE HIPPO PATHWAY
Core Components: Mst1/2 and Lats1/2
Warts (Wts), core components of the Hippo pathway identified
in Drosophila, and their homologs in mammals, large tumor
suppressor kinases 1 and 2 (Lats1/2), are protein kinases of
the nuclear Dbf2-related (NDR) family (Figure 1). Lats1/2
are activated by phosphorylation by macrophage stimulating
proteins 1/2 (Mst1/2), members of the Ste20 protein kinase
family (Qin et al., 2013). By binding to Lats1/2, Mob1 enhances
the affinity of the latter to Mst1/2. Mst1/2 are themselves
phosphorylated by upstream activators, and binding with the
adaptor protein Sav enhances their affinity with Lats1/2 (Qin
et al., 2013).
Yap and Taz Are Phosphorylated and
Inhibited by the Hippo Pathway
Yes-Associated Protein (Yap) and its ortholog Transcriptional co-
activator with PDZ binding motif (Taz) are the main effectors of
the Hippo pathway. The critical event is the phosphorylation of
those effectors by Lats1/2 (Piccolo et al., 2014; Figure 2).
Phosphorylation and Cytoplasmic Retention
Yap contains five HXRXXS sequences that can be phosphorylated
by Lats kinases while Taz contains four of them. Phosphorylation
of Yap at S127 and of Taz at S89 leads to binding with 14-3-3
protein in the cytoplasm, maintaining Yap/Taz in the cytoplasm
(Zhao et al., 2011).
Non-phosphorylation-dependent Cytoplasmic
Retention
Yap/Taz can also be inhibited and maintained close to cellular
membrane by protein-protein bindings with the Angiomotin’s
(AMOT) protein family (Zhao et al., 2011).
Phosphorylation and Degradation
When Yap is phosphorylated at S381, and Taz at S311 by Lats1/2,
casein kinase 1 (CK1δ/ε) can in turn phosphorylate Yap at S400
and S403 and Taz at S314 (Zhao et al., 2011). This induces
the formation of a phosphodegron, the function of which is
FIGURE 1 | Canonical Hippo pathway. Core components of the Hippo
pathway in mammals. Mst1/2 is phosphorylated by upstream regulators and
binding with Sav enhances its affinity for Lats1/2, which in turn binds with
Mob1. Activation of Mst1/2 and Lats1/2 results in phosphorylation and
inactivation of Yap/Taz. See text for abbreviations.
to recruit β-transducin repeat-containing protein (β-TRCP) E3
ubiquitin ligase. The formation of phosphodegron, in association
with activation of β-TRCP, leads to Yap/Taz degradation by the
proteasome in the cytoplasm (Kodaka and Hata, 2015).
In summary, activation of the Hippo pathway induces Yap/Taz
phosphorylation and inhibition of the latter complex, which
results in its sequestration in the cytoplasm and subsequent
degradation by the proteasome.
UPSTREAM REGULATORS OF THE HIPPO
PATHWAY
Numerous cues, amongst which metabolites, nutrients and
mechanical signals, are thought to regulate the Hippo pathway,
even if the molecular mechanisms are still unclear (Fischer
et al., 2016). In mammals, neurofibromatosis 2 (NF2) mutations
induce benign tumors while those tumors are repressed by Yap
suppression. It has therefore been postulated that NF2 could
be an upstream regulator of Hippo and Yap (Benhamouche
et al., 2010). Recent studies showed that AMOT can bind NF2
directly, promoting interaction and activation of Mst1/2 and
sequestration of Yap/Taz in the cytoplasm (Li et al., 2015). All
together, regulation of Yap activation by NF2 is clearly more
complex than it was thought.
G-protein-coupled-receptors (GPCRs), a vast family of
membrane receptors, are identified as regulators of the Hippo
pathway and Yap/Taz (Santinon et al., 2016). The regulation
Frontiers in Physiology | www.frontiersin.org 2 March 2017 | Volume 8 | Article 190
Gnimassou et al. Hippo Pathway and Muscle Mass
FIGURE 2 | Regulation and functions of the Hippo pathway. Hippo pathway core components, Mst1/2 and Lats1/2, are regulated by membrane protein (NF2,
AMOT), membrane receptors (GPCR and downstream effectors Rho GTPases), metabolites (epinephrine, glucagon, LPA and S1P), low ATP levels and extracellular
matrix. When phosphorylated (1) at S127 (S89 for Taz), Yap is bound to 14-3-3 protein for cytoplasmic retention; (2) at S381 (S311 for Taz), β-TRCP is recruited and
Yap/Taz is ubiquitinated for proteasomal degradation. In the non-phosphorylated state, Yap translocates into the nucleus, and binds to TEAD proteins to induce
transcription of several genes (CGTF, Gli2, diap1, Birc5, Birc2, FGF1, AREG, Ankrd1, and LAT1). Yap can bind an unknown transcription factor to induce transcription
of Myc. Finally Yap can directly bind proteins like RUNX, ErbB4, and p73. See text for abbreviations.
by GPCRs may activate or inhibit the Hippo pathway and
actin filaments and Rho GTPases are thought to mediate the
interaction between GPCRs and Yap/Taz (Yu et al., 2012).
The Hippo pathway is also differentially regulated according
to the ligands that bind to the GPCRs, amongst which
several extracellular metabolites (Santinon et al., 2016). The
first metabolite discovered was mevalonate that is responsible
for acetyl-CoA conversion in isoprenoides precursors such as
cholesterol, biliary acid or steroids, which can all activate the
Hippo pathway (Santinon et al., 2016). Similarly, epinephrine
and glucagon, mediated by Gαs-coupled signals, activate
Lats1/2 and consequently inhibit Yap/Taz. On the contrary,
lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P),
mediated by Gα12/13-, Gαq/11-, and Gαi/o-coupled signals,
repress Lats1/2 (Santinon et al., 2016).
The AMP-activated protein kinase (AMPK) pathway is
implicated in cellular homeostasis and can inhibit the Hippo
pathway (Wang et al., 2015a). In energy stress conditions, i.e low
levels of ATP, AMPK promotes the inhibitory activity of tuberous
sclerosis complex (TSC1-TSC2), an upstream component of the
mTOR pathway. AMPK also phosphorylates Yap at S94 and S61
and maintains the latter in the cytoplasm (Wang et al., 2015a).
These two mechanisms trigger catabolic pathways aiming to
recover energy homeostasis and basal AMPK activity (Santinon
et al., 2016).
Finally, the Hippo pathway is regulated by cell-cell contact
and extracellular matrix. Indeed, Yap is phosphorylated and
maintained in the cytoplasm in densely populated cells, while
lysis of cell-cell junctions induces Yap/Taz translocation to the
nucleus. Therefore, an overexpression of Yap in the nucleus is
observed in sparsely populated cells (Low et al., 2014).
DOWNSTREAM EFFECTORS OF THE
HIPPO PATHWAY
Yap/Taz are co-activators and as such, do not possess DNA
binding sites. To induce their transcriptional program, Yap/Taz
have to bind to transcription factors such as to the TEADs
family proteins (Tumaneng et al., 2012; Chaillou et al., 2015;
Hansen et al., 2015). Yap and TEADs together can induce
the transcription of specific genes such as connective tissue
growth factor (CTGF), Gli2, mammalian homolog of Diap1 and
baculoviral IAP repeat-containing 5 and 2 (Birc5 and Birc2),
ankyrin repeat domain 1 (Ankrd1), and L-type amino acid
transporter 1 (LAT1). Yap can bind an unknown transcription
factor to induce transcription of Myc (Tumaneng et al.,
2012). Finally, Yap can bind other proteins like runt-related
transcription factor (RUNX), ErbB4 and p73 but none of those
complexes seems to regulate organ size or development (Zhao
et al., 2011).
Yap/Taz, andmore broadly theHippo pathway, are involved in
many interactions and crosstalks with other signaling pathways
to regulate cell cycle and cell fate (Fischer et al., 2016). These
interactions and crosstalks are described in the next section.
INTERPLAY WITH OTHER SIGNALING
PATHWAYS
Hippo and Transforming Growth Factor-β
Pathways
TGF-β plays an important role in the proliferation of stem cells
and tumor genesis via Smads activation as effectors (Saito and
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Nagase, 2015). When phosphorylated, Smad1 affinity to Yap is
enhanced, which in turns activates proliferation and renewal of
embryonic stem cells (Grannas et al., 2015). Similarly, Taz, and
Smad2/3 binding induces their nuclear localization, transcription
of TGF-β targets genes, and renewal of embryonic stem cells.
However, the exact nature of interactions between Yap/Taz and
Smads and their contribution to organ size regulation remain
unclear (Saito and Nagase, 2015).
Hippo and Wnt Pathways
Wnt is decisive in stem cell proliferation, differentiation and
fate, the aberrant stimulation of which induces tumors genesis
(Hergovich and Hemmings, 2010). Stimulation of Wnt receptors
by their ligands elicits a disheveled (Dvl)-dependent inhibition of
β-catenin complexes degradation, β-catenin accumulation in the
nucleus and interaction with T-cell factor/Lymphoid enhancer
factor (TCF/Lef) and finally transcription of Wnt-regulated
genes. Contrarily to Wnt, Taz inhibits Dvl1, 2 and 3 by binding
and retaining β-catenin in the cytoplasm, preventing the latter to
exert its transcriptional activity (Imajo et al., 2012). Seeing that
Mst1/2 and Lats1/2 can phosphorylate Taz, they are thought to
be able to repress Wnt as well (Kim and Jho, 2014). In summary,
the Hippo pathway can repress Wnt signaling by blocking
Dvl or maintaining β-catenin in the cytoplasm, however, the
contribution of the interaction between the Hippo and Wnt
pathways to organ size regulation remains unknown (Xu et al.,
2014).
Hippo and Sonic-Hedgehog Pathways
The Sonic-Hedgehog pathway is the main regulator of cell
differentiation, proliferation and polarity (Zhao et al., 2010). In
medulloblastoma elicited by excessive Sonic-Hedgehog and Wnt
activation, an overexpression of Yap and TEAD1 is observed
(Fernandez et al., 2009). Moreover, Yap and TEAD1 binding
may induce expression of Gli2, a Sonic-Hedgehog effector, which
re-enforces the hypothesis of an interaction between Hippo
and Hedgehog. However, it remains unknown whether other
components of the Hippo pathway are involved in the interaction
with the Sonic-Hedgehog pathway (Zhao et al., 2010).
Hippo and Akt-mTOR Pathways
The Hippo and the Akt-mTOR pathways are responsible for
the regulation of cell numbers and cell size, respectively. mTOR
regulates cell size in response to nutrients and growth factors (Lee
et al., 2007). Hippo regulates cell number by phosphorylating
Yap/Taz, which in turn will result in a repression of cell
proliferation and a stimulation of apoptosis in mammals (Csibi
and Blenis, 2012). An overexpression of the effectors of Hippo,
i.e., Yap/Taz, increases the phosphorylation of Akt and S6 Kinase1
(S6K1). Inversely, Yap is maintained in the cytoplasm by 14-3-3
protein and its transcription repressed when phosphorylated by
Akt (Kodaka and Hata, 2015). On the other hand, Yap has been
shown to promote skeletal muscle hypertrophy independently of
any change in mTOR activity (Watt et al., 2015). In summary,
while it is clear that the Hippo and Akt-mTOR pathways may
interact, the direction and the consequences of the interaction do
not seem straightforward.
HIPPO PATHWAY AND REGULATION OF
ORGAN SIZE
Hippo and Organ Size Control
The role of the Hippo pathway in organ size management has
been convincingly demonstrated by studies in mice. Specific
alteration of Mst1/2, Lats1/2, or Sav in liver cells provokes up
to a four-fold growth (Zhao et al., 2011). In another study, the
transcriptional activity of Yap was increased during regrowth
after partial liver ablation while at the same time, Mst1/2 and
Lats1/2 were inhibited (Grijalva et al., 2014). This higher activity
of Yap was quasi-automatically repressed at the end of regrowth
andMst1/2 and Lats1/2 inhibition released (Grijalva et al., 2014).
The situation is more complex in the pancreas as Hippo pathway
activity seems to be compartment-dependent. Indeed, Mst1/2
inhibition induced hyperplasia and cell death in the exocrine
compartment while there was no incidence in the endocrine
compartment (George et al., 2012). In the intestine, Yap ablation
did not repress development but limited post-lesion regrowth
(Cai et al., 2010). All together, those studies show the role of the
Hippo pathway in the regulation of organ size.
Hippo and Stem Cells
The Hippo pathway is thought to manage stem cell regulation,
renewal, and expansion. Indeed, Yap is activated in satellite
cells and inhibited during differentiation of embryonic stem
cells. Furthermore, embryonic stem cells stay quiescent under
regulation by Taz (Hiemer and Varelas, 2013). In intestinal
progenitors, hepatic oval cells, neural and epidermal stem
cells, Yap is generally required for their stemness, promoting
proliferation but inhibiting differentiation (Judson et al., 2012).
HIPPO PATHWAY AND SKELETAL MUSCLE
MASS REGULATION
The Hippo components have been identified in myogenic cells
in vitro and in skeletal muscle in vivo (Watt et al., 2010) but
their role in muscle mass regulation is less investigated. Given
its multiple interactions with other signaling pathways, it is
postulated that the Hippo pathway could play a role in different
regulatory mechanisms, namely proliferation and renewal of
satellite cells, differentiation, death and growth of myogenic cells
(Yu and Guan, 2013).
Role of the Hippo Pathway during
Myogenesis
As observed in other tissues, themRNA and protein expression of
Yap were high during myogenic cell proliferation and low during
differentiation (Watt et al., 2010; Judson et al., 2012). In addition,
during C2C12 cell proliferation, Yap Ser127 phosphorylation was
low and Yap localized to nuclei. Upon differentiation, Yap Ser127
phosphorylation increased about 20-fold and Yap translocated
from the nucleus to the cytosol. During the differentiation phase,
overexpression of hYap1 S127A, a mutant form of Yap which
cannot be phosphorylated at S127 by Lats1/2, induced a decrease
in myogenin and Mef2c expression, two differentiation genes,
and a persistent expression of Myf5, a myoblast proliferation
gene (Watt et al., 2010). Those results are consistent with the
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hypothesis that phosphorylation of Yap at S127 is necessary
for myoblasts to withdraw the cell cycle and to differentiate
(Watt et al., 2010). Similar results were obtained in satellite
cells isolated from mouse muscle (Judson et al., 2012). In that
study, constitutive Yap activity expanded the pool of activated
satellite cells and satellite cell-derived myoblasts but prevented
their differentiation. Microarray analyses identified regulators of
the cell cycle, ribosomal biogenesis and modulators of myogenic
differentiation as genes targeted by Yap. Yap was found to
bind TEAD and co-activate muscle-specific cytidine-adenosine-
thymidine (MCAT)-elements in myoblasts. In another study in
postnatal myogenic cells of mice, a high expression of Mst1/2 was
found followed by a decrease within the first 3 weeks of life (Wei
et al., 2013). All together, those results suggest a role of the Hippo
pathway in in vitro myogenesis as well as in postnatal muscle
development in vivo.
Role of the Hippo Pathway in Mouse
Skeletal Muscle
Due to its regulatory role in the determination of cell size in
general, it can logically be expected that the Hippo pathway
regulates muscle cell growth as well. To investigate this
hypothesis, an inducible skeletal muscle fiber-specific knock-
in mouse model (MCK-tTA-hYAP1 S127A) was developed to
test whether the over expression of constitutively active Yap
(hYAP1 S127A) is sufficient to stimulate muscle hypertrophy
or changes in fiber type composition (Judson et al., 2013).
Unexpectedly, expression of this mutant form of Yap caused, ∼5
weeks later, a kind of myopathy together with muscle atrophy,
which was followed by a regenerative process comprised of
activation, proliferation and differentiation of satellite cells. At a
molecular level, Myf5, myogenin, and Pax7, markers of satellite
cells activation and differentiation, were highly expressed at the
mRNA level as well as Atrogin-1 and MuRF-1, two markers of
protein degradation. Of note, fiber type composition remained
unchanged and the processes of atrophy and degeneration
remained reversible when preventing the expression of the
mutant form of Yap (Judson et al., 2013).
Contrary to the previous study, overexpressing total Yap,
instead of active Yap, could induce hypertrophy via interaction
with TEADs and independently of any activation of mTOR (Watt
et al., 2015). It was also found that total Yap expression and
phosphorylation at S112 decreased during maturation of the
myofibrils (Watt et al., 2015). Furthermore, repression of Yap
expression caused a reduction in the size of myofibrils, and
ultimately a decrease in muscle mass. This reduction in mass
was associated with slightly increased, though not significant,
expression of the markers of protein degradation Atrogin-
1, Musa1, and MuRF-1 (Watt et al., 2015). It was therefore
concluded that the expression of Yap would be necessary for
maintaining and increasing the size of the myofibrils.
Imposing a significant burden to the plantaris by agonist
ablation, a higher expression of Yap was found together with
a higher transcriptional activity of TEADs into the plantaris,
thereby highlighting Yap sensitivity to mechanical loading on
the muscle (Goodman et al., 2015). This phenomenon was
accompanied by an increase in Akt phosphorylation in a
similar pattern as Yap expression and by hypertrophy that
persisted following inhibition of mTOR by rapamycin injection.
Corroborating previous results (Wang et al., 2015b), it seems
that Yap can induce hypertrophy independently of mTOR. This
hypertrophy was probably due, at least in part, to a low expression
ofMuRF-1 and a high expression ofMyoD and c-Myc (Goodman
et al., 2015).
It therefore appears that Hippo interacts with other pathways
for the management of muscle mass. While some studies
suggest that Yap overexpression/activation induces muscle
atrophy (Judson et al., 2013), others found opposite results, i.e.
hypertrophy after Yap overexpression (Goodman et al., 2015;
Watt et al., 2015). Those discrepancies can, at least partially,
be explained by the different ways, viral vectors vs. gene
mutations, used to induce Yap expression and the duration of
the treatment (Watt et al., 2010, 2015; Judson et al., 2013; Wei
et al., 2013; Goodman et al., 2015). But other unknown factors are
probably involved as well. This topic definitely deserves further
investigation.
PERSPECTIVES AND CONCLUSION
Only one study has investigated the effect of exercise on the
Hippo pathway (Hulmi et al., 2013). This study was performed
in mice and the chosen exercise paradigm was running, which
is not expected to increase muscle mass contrary to resistance
exercise. Based on its role in skeletal muscle and satellite cells,
we hypothesize that the Hippo pathway could contribute to the
accretion of muscle mass after resistance exercise training, which
still remains to be tested. In this perspective, the next step is to
test whether the results obtained in vitro and in mice can be
confirmed in healthy human skeletal muscle. Due to its role in
the management of satellite cells, we speculate that the Hippo
pathway could play a determinant role in the activation of this
specific cell type after resistance exercise. Finally, it would be
interesting to test the involvement of the Hippo pathway after
resistance exercise with blood flow restriction. Indeed, this kind
of training has proven its efficiency to increase muscle mass by,
amongst others, activating satellite cells and stimulating their
proliferation (Nielsen et al., 2012). Here as well, it is unknown
whether the Hippo pathway mediates this effect.
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